HopeStage
Back to all studies
RecruitingNCT04084860

Study of glutamate-modulating medicines for alcohol use

About this titleRead the official source — NCT04084860
Medication studyAges 21–70United StatesAddiction
The study in practice

Understand this study

Who could participate?

Listed age limits: 21 years to 70 years.

Listed locations
New YorkSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: November 8, 2019
Recruitment status
Recruiting
Enrollment listed in the registry
120
Sponsor
New York State Psychiatric Institute
Sponsor type
Research institute
Study type
Behavioral
Intervention type
Behavioural, Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 21 Years to 70 Years
Official registry ID
NCT04084860
Official title
Show the full official title

The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking: a Randomized, Controlled Trial

Recruitment & locations

Currently recruiting

New York

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is New York State Psychiatric Institute, a research institute.

Does this study involve medication?

Yes. The study involves medication, including CI-581a and CI-581b.

Who can participate?

Listed age limits: 21 years to 70 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies